Polatuzumab Vedotin (Genetical Recombination)



Polatuzumab Vedotin is an antibody-drug-conjugate (molecular weight: ca. 153,000) consisting of Vedotin (1-(6-{[(2S)-1-({(2S)-5-carbamoylamino-1-[(4-{[(2S)-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]methylcarbamoyloxy}methylphenyl)amino]-1-oxopentan-2-yl}amino)-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl group (C₆₈H₁₀₆N₁₁O₁₅; molecular weight: 1317.63)) , which is composed of monomethyl auristatin E ([(S)-1-{[(S)-1-{[(3R,4S,5S)-1-{(S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl][methyl]amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)amine) and 4-[(S)-2-{(S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido}-5-ureidopentanamido]benzyloxycarbonyl linker, attached to an average of 3-4 Cys residues of a recombinant monoclonal antibody (molecular weight: ca. 148,000).The monoclonal antibody moiety is a humanized monoclonal antibody composed of complementarity-determining regions derived from a mouse anti-human CD79b monoclonal antibody and framework regions and constant regions derived from a human IgG1 and produced in Chinese hamster ovary cells. The protein moiety is a glycoprotein composed of 2 H-chains (γ1-chains) consisting of 447 amino acid residues each and 2 L-chains (κ-chains) consisting of 218 amino acid residues each.

[1313206-42-6]